Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
基本信息
- 批准号:10356164
- 负责人:
- 金额:$ 56.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:Angiogenesis InhibitorsBioinformaticsBlood VesselsBreast Cancer ModelCCL2 geneCXCL12 geneCXCR4 geneCancer EtiologyCellsCessation of lifeCharacteristicsCommunicationDepositionDiseaseDisease ProgressionEndothelial CellsExtracellular MatrixFactor XIIIaFibrinFibrinolysisGeneticHeterogeneityHydrogelsImmuneInflammatoryKineticsLungLung AdenocarcinomaMediatingMicrofluidicsModelingMolecular ProbesMusNatureNeoplasm MetastasisOncogenesPharmacologyPlasminogen Activator Inhibitor 1RNA-Binding ProteinsRegulationReporterReportingRoleSignal TransductionSquamous Cell Lung CarcinomaTransforming Growth Factor betaTumor Angiogenesisangiogenesisbasecancer typecell motilityclinical investigationcrosslinkdensitydisorder controlextracellular vesicleshuman diseaseimmune checkpoint blockadeimprovedin vivoindexinginhibitorinsightmonocytemortalitymouse modelneoplastic cellnovelprogramsrecruitscaffoldsupport networktargeted treatmenttriple-negative invasive breast carcinomatumortumor growthtumor microenvironmenttumor progressionultrasoundwound healing
项目摘要
Project Summary
Lung and triple-negative breast cancers (TNBCs) are leading causes of cancer-related deaths in the U.S. This
high mortality rate is largely due to their propensity to rapidly progress and metastasize. While targeted therapies
for lung adenocarcinoma have improved overall survival, similar advances in lung squamous carcinoma (LUSC)
and TNBC have been stagnant. However, for both cancer types, immune checkpoint blockade and/or
angiogenesis inhibitors improves disease control. Thus, a more complete understanding of how vascular/immune
niches within the tumor microenvironment (TME) promotes LUSC and TNBC will allow us to build upon these
advances. Our teams have recently demonstrated that LUSC and TNBC promote tumor growth and metastases
through a convergence on fibrin remodeling (Nature Communications, 2018; J Clinical Investigation, 2019) and
activation of endothelial cell wound-healing programs (Oncogene, 2019). Fibrin(ogen) that escapes leaky tumor
endothelial cells (TECs) acts as a scaffold for tumor cell motility and creates a provisional matrix for tumor
progression. Using highly integrated bioinformatics and novel LUSC models, we recently found that CCL2-
mediated recruitment of Factor XIIIA (FXIIIA)-expressing inflammatory monocytes (IMs) promotes fibrin cross-
linking, metastases and poor survival in LUSC. We also found that TEC heterogeneity (TECH) directs fibrin
accumulation through a TGFβ/miR-30c/PAI-1 signaling axis - TECs with high levels of the fibrinolysis inhibitor,
PAI-1, increase perivascular fibrin networks that support sprouting angiogenesis and tumor progression. We
have also uncovered a secondary connection between fibrin remodeling and the RNA-binding protein Quaking
(QKI) which is enriched in TECs and drives tumor angiogenesis. Silencing QKI in TECs inhibits sprouting
angiogenesis and metastases, but micro-vessel density (MVD) paradoxically increases; which we posit is due to
CXCL12-mediated sequestering of CXCR4+ IMs that initiate fibrin cross-linking. Based on these collective new
insights from our groups, we hypothesize that (i) inhibition of TEC QKI initially blocks tumor angiogenesis and
metastasis, however, a CXCL12-mediated retention of FXIIIA+ IMs promotes fibrin remodeling and rebound
angiogenesis. Additionally, we propose (ii) that TECH drives the formation of aberrant and persistent perivascular
fibrin scaffolds in LUSC and TNBC via a spectrum of TGFβ/miR-30c/PAI-1 expression. The objective of this
proposal is to elucidate how fibrin remodeling and tumor progression depend on the heterotypic relationships
between TECs and IMs, and the heterogeneity amongst TECs within the TME.
项目摘要
肺癌和三阴性乳腺癌(TNBC)是美国癌症相关死亡的主要原因。
高死亡率主要是由于它们倾向于迅速进展和转移。虽然靶向治疗
肺腺癌的总生存率有所提高,肺鳞癌(LUSC)的进展相似
和TNBC一直停滞不前。然而,对于这两种癌症类型,免疫检查点阻断和/或免疫检查点阻断都是有效的。
血管生成抑制剂改善疾病控制。因此,更全面地了解血管/免疫
肿瘤微环境(TME)内的小生境促进LUSC和TNBC将使我们能够在这些基础上建立
预付款。我们的团队最近证明LUSC和TNBC促进肿瘤生长和转移
通过对纤维蛋白重塑的融合(Nature Communications,2018; J Clinical Investigation,2019),
激活内皮细胞伤口愈合程序(Oncogene,2019)。逃避渗漏肿瘤的纤维素(原)
内皮细胞(TEC)作为肿瘤细胞运动的支架,并为肿瘤细胞提供临时基质,
进展使用高度集成的生物信息学和新的LUSC模型,我们最近发现CCL 2-
表达因子XIIIA(FXIIIA)的炎性单核细胞(IM)介导的募集促进纤维蛋白交叉,
在LUSC中的连接、转移和低生存率。我们还发现TEC异质性(TECH)指导纤维蛋白
通过TGFβ/miR-30 c/派-1信号传导轴-具有高水平纤维蛋白溶解抑制剂的TEC积累,
派-1,增加血管周围纤维蛋白网络,支持萌芽血管生成和肿瘤进展。我们
还发现了纤维蛋白重塑和RNA结合蛋白Quaking之间的第二种联系
(QKI)其富含TEC并驱动肿瘤血管生成。沉默TEC中的QKI抑制发芽
血管生成和转移,但微血管密度(MVD)矛盾地增加;我们认为这是由于
CXCL 12介导的CXCR 4 + IM的隔离,其启动纤维蛋白交联。基于这些新的集体
根据我们小组的见解,我们假设(i)抑制TEC QKI最初阻断肿瘤血管生成,
然而,在转移中,CXCL 12介导的FXIIIA+ IM的保留促进纤维蛋白重塑和反弹,
血管生成此外,我们提出(ii)TECH驱动异常和持续性血管周围血管的形成,
通过TGFβ/miR-30 c/派-1表达谱,在LUSC和TNBC中的纤维蛋白支架中观察。的目的
建议是阐明纤维蛋白重塑和肿瘤进展如何依赖于异型关系
以及TME内TEC之间的异质性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Carl Dudley其他文献
Andrew Carl Dudley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Carl Dudley', 18)}}的其他基金
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10179715 - 财政年份:2021
- 资助金额:
$ 56.85万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10573196 - 财政年份:2021
- 资助金额:
$ 56.85万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8693221 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8887312 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10399410 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10092966 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10621205 - 财政年份:2014
- 资助金额:
$ 56.85万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
7708266 - 财政年份:2009
- 资助金额:
$ 56.85万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
8231654 - 财政年份:2009
- 资助金额:
$ 56.85万 - 项目类别:
相似海外基金
Conference: Global Bioinformatics Education Summit 2024 — Energizing Communities to Power the Bioeconomy Workforce
会议:2024 年全球生物信息学教育峰会 — 激励社区为生物经济劳动力提供动力
- 批准号:
2421267 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant
Open Access Block Award 2024 - EMBL - European Bioinformatics Institute
2024 年开放获取区块奖 - EMBL - 欧洲生物信息学研究所
- 批准号:
EP/Z532678/1 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Research Grant
Conference: The 9th Workshop on Biostatistics and Bioinformatics
会议:第九届生物统计与生物信息学研讨会
- 批准号:
2409876 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant
PAML 5: A friendly and powerful bioinformatics resource for phylogenomics
PAML 5:用于系统基因组学的友好且强大的生物信息学资源
- 批准号:
BB/X018571/1 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Research Grant
PDB Management by The Research Collaboratory for Structural Bioinformatics
结构生物信息学研究合作实验室的 PDB 管理
- 批准号:
2321666 - 财政年份:2024
- 资助金额:
$ 56.85万 - 项目类别:
Cooperative Agreement
Building a Bioinformatics Ecosystem for Agri-Ecologists
为农业生态学家构建生物信息学生态系统
- 批准号:
BB/X018768/1 - 财政年份:2023
- 资助金额:
$ 56.85万 - 项目类别:
Research Grant
Integrative viral genomics and bioinformatics platform
综合病毒基因组学和生物信息学平台
- 批准号:
MC_UU_00034/5 - 财政年份:2023
- 资助金额:
$ 56.85万 - 项目类别:
Intramural
Collaborative Research: IIBR: Innovation: Bioinformatics: Linking Chemical and Biological Space: Deep Learning and Experimentation for Property-Controlled Molecule Generation
合作研究:IIBR:创新:生物信息学:连接化学和生物空间:属性控制分子生成的深度学习和实验
- 批准号:
2318829 - 财政年份:2023
- 资助金额:
$ 56.85万 - 项目类别:
Continuing Grant
Planning Proposal: CREST Center in Bioinformatics
规划方案:CREST生物信息学中心
- 批准号:
2334642 - 财政年份:2023
- 资助金额:
$ 56.85万 - 项目类别:
Standard Grant